Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu

EUCCAT - European Center for Gene and Cellular Cancer Therapies 

Find the topic you are looking for
Find a contact

You are here:

Aims and ojectives

EUCCAT network composition
EUCATT network composition

Cell and gene therapies show enormous potential in the treatment of many diseases, such as cancer, autoimmune diseases and many other rare diseases. Due to the novelty and complexity of novel therapies, the path to approval and clinical use is very long and costly, raising concerns that wider use of these therapies is not sustainable for healthcare systems in the EU.

The goal of EUCCAT (European Center for Gene & Cellular Cancer Therapies) is to make new cancer therapies affordable and accessible to all patients.  To this end, we aim to establish decentralised manufacturing of advanced therapy medicinal products (ATMPs) in hospitals, thus reducing manufacturing costs and waiting times.  EUCCAT is a virtual, transnational institute that brings together basic research groups, drug manufacturing facilities, clinical trial capacity and implementation expertise. Through EUCCAT, we aim to strengthen and advance Europe's competitiveness in research and development and clinical applications of cell and gene therapies.

At Charité, the EUCCAT team is composed of a synergy of clinical and preclinical, regulatory and innovation/technology transfer groups to enable, among other things, the conduct of multicentre clinical trials with our cooperation partners from the EUHA.

EUCCAT Charité is supported by Innovation Transfer in all contractual and IP issues and provides the legal framework in development cooperation for conducting the studies, securing IP and exploiting the study results.


Composition of the EUCCAT working group of the Charité

  • PD Dr. med. Annette Künkele-Langer (EUCCAT Koordinatorin), Klinik für Pädiatrie m.S. Onkologie und Hämatologie / Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK 
  • Dr. Leila Amini, Leitung AG Clinical Development Platform Cell and Gene Therapies, Berlin Center for Advanced Therapies (BeCAT) / BIH - AG Petra Reinke 
  • Dr. rer. nat. Catharina Delebinski, Klinik für Pädiatrie m.S. Onkologie und Hämatologie / BIH - Charité BIH Innovation - Team SPARK / Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK 
  • Gady Goldsobel, Innovationsplattform, BIH Center for Regenerative Therapies uda 
  • Dr. rer. nat. Stefanie Grunwald, Charité BIH Innovation - Team Patente & Lizenzen 
  • Dr. rer. nat. Andreas Hüser, Leitung Innovationsplattform, BIH Center for Regenerative Therapies 
  • Maja Pizevska, Klinische Entwicklung & regulatorische Angelegenheiten, BIH Center for Regenerative Therapies  

Ongoing projects

  • MC2 TCR T-cell phase I/II: Study in collaboration with Erasmus MC Rotterdam and Greater Paris University Hospitals (PI Reno Debets); contact: PD Dr. Annette Künkele-Langer.
  • Healthcare Transformation Academy (HTA): Project in collaboration with Karolinska University Hospital and Vall d'Hebron Barcelona Hospital Campus; Contact: Dr. Leila Amini.

Further Information

EUHA- Innovative Therapies 


Annette Künkele
Prof. Dr. med. Annette Künkele

Pediatrician, Specialized physician for pediatric oncologyCharité – Universitätsmedizin Berlin

Postal address:Augustenburger Platz 113353 Berlin